Wayne M. Clark

Wayne M. Clark

Auto-generated profile, based on publicly available information

Wayne M. Clark

Oregon Health and Science University, Portland (W.M.C.).

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1999 in JAMA
Verified
Journal Article
Closed access
PDF file
WCWayne M. Clark
Wayne M. Clark
SWStanley Wissman
Stanley Wissman
GAGregory W. Albers
Gregory W. Albers
JJJack H. Jhamandas
Jack H. Jhamandas
KMKenneth P. Madden
Kenneth P. Madden
FIfor the ATLANTIS Study Investigators
for the ATLANTIS Study Investigators
Research from JAMA — Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset — The ATLANTIS Study — A Randomized Controlled Trial — ContextRecombinant tissue-type plasminogen activator (rt-PA) improves outcomes for patients with acute ischemic stroke, but current approved use is limited to within 3 hours of symptom onset. This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset.ObjectiveTo test the efficacy and safety of rt-PA in patients with acute ischemic stroke when administered between 3 and 5 hours after symptom onset.DesignThe Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study is a phase 3, placebo-controlled, double-blind randomized study conducted between December 1993 and July 1998, with up to 90 days of follow-up.SettingOne hundred forty university and community hospitals in North America.PatientsAn intent-to-treat population of 613 acute ischemic stroke patients was enrolled, with 547 of these treated as assigned within 3 to 5 hours of symptom onset. A total of 39 others were treated within 3 hours of symptom onset, 24 were treated more than 5 hours after symptom onset, and 3 never received any study drug.InterventionAdministration of 0.9 mg/kg of rt-PA (n = 272) or placebo (n = 275) intravenously over 1 hour.Main Outcome MeasuresPrimary efficacy was an excellent neurologic recovery at day 90 (National Institutes of Health Stroke Scale [NIHSS] score of ≤1); secondary end points included excellent recovery on functional outcome measures (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at days 30 and 90. Serious adverse events were also assessed.ResultsIn the target population, 32% of the placebo and 34% of rt-PA patients had an excellent recovery at 90 days (P = .65). There were no differences on any of the secondary functional outcome measures. In the first 10 days treatment with rt-PA significantly increased the rate of symptomatic intracerebral hemorrhage (ICH) (1.1% vs 7.0% [P<.001]), a symptomatic ICH (4.7% vs 11.4% [P = .004]), and fatal ICH (0.3% vs 3.0% [P<.001]). Mortality at 90 days was 6.9% with placebo and 11.0% with rt-PA (P = .09). Results in the intent-to-treat population were similar.ConclusionsThis study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treatment. These results do not support the use of intravenous rt-PA for stroke treatment beyond 3 hours.

1 October 1998 in Stroke
Verified
Journal Article
Closed access
WCWayne Clark
Wayne Clark
LGLisa Gunion-Rinker
Lisa Gunion-Rinker
NLNikola Lessov
Nikola Lessov
KHKristin Hazel
Kristin Hazel
Background and Purpose —Citicoline sodium (cytidine-5′-diphosphocholine) has been shown previously to reduce ischemic injury in focal central nervous system models. Intracerebral hemorrhage (ICH) appears to be associated with an area of edema and ischemic injury surrounding the hematoma that may be reduced by neuroprotective therapy. The present study was designed to test whether treatment with citicoline reduces ischemic injury and improves functional neurological outcome in an experimental model of ICH. Methods —In 68 Swiss albino mice (26 to 36 g), ICH was induced by collagenase injection into the caudate nucleus. Animals were randomized to receive either: citicoline 500 mg/kg or saline IP prior to collagenase and at 24 and 48 hours. Animals were rated on a 28-point neurological scale and sacrificed at 54 hours. The brains were sectioned, and the volume of hematoma, total lesion, and surrounding ischemic injury was determined. Results —In terms of functional outcome, animals treated with citicoline had improved neurological outcome scores compared with placebo-treated animals: 10.4±2.0 versus 12.1±2.4 ( P <0.01). Regarding ischemic injury, although there was no difference in the underlying hematoma volumes, animals treated with citicoline had a smaller surrounding volume of ischemic injury than placebo-treated animals: citicoline, 13.8±5.8 mm 3 (10.8±4.3% of hemisphere); placebo, 17.0±7.1 mm 3 (13.3±5.1%) ( P <0.05). Conclusions —In this animal model of ICH, treatment with citicoline significantly improved functional outcome and reduced the volume of ischemic injury surrounding the hematoma. This study supports a potential role for citicoline in clinical ICH treatment.

13 November 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
WCW. M. Clark
W. M. Clark
LWL. R. Wechsler
L. R. Wechsler
LSL. A. Sabounjian
L. A. Sabounjian
USU. E. Schwiderski
U. E. Schwiderski
Background: Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects. Objective: To determine the safety and efficacy of citicoline treatment in acute stroke patients. Method: An 118-center, randomized, double-blind, efficacy trial in 899 patients compared placebo (n = 446) with citicoline (n = 453) (1000 mg PO twice a day) for 6 weeks, with a 6-week post-treatment follow-up period. Patients with acute (≤24 hours) ischemic strokes clinically thought to be in the middle cerebral artery territory with NIH Stroke Scale (NIHSS) scores ≥8 were enrolled. Results: Mean time to treatment was 13 hours for both groups and mean age was 67 years for those receiving placebo and 68 years for those receiving citicoline. Mean baseline NIHSS scores were 14.5 for placebo and 13.9 for citicoline (p = 0.06); medians were 14 for placebo and 13 for citicoline (p = 0.04). The incidence and type of side effects were similar between the groups. There were no between-group differences on the planned primary analysis, percent of patients with a ≥7-point NIHSS score change at 90 days (placebo 51%, citicoline 52%). There were no between-group differences on the other planned secondary analyses at 90 days, including mortality. However, post hoc analyses using standard “excellent recovery” measures suggested a possible treatment effect on the modified Rankin 0 or 1 (last observation carried forward: placebo 20%, citicoline 26%; p = 0.025) as well as a global outcome statistic. Conclusions: Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.

1 December 1999 in Stroke
Verified
Journal Article
Closed access
PDF file
WCWayne M. Clark
Wayne M. Clark
BWBenjamin J. Williams
Benjamin J. Williams
KSKenneth A. Selzer
Kenneth A. Selzer
RZRichard M. Zweifler
Richard M. Zweifler
LSLuAnn A. Sabounjian
LuAnn A. Sabounjian
RGRichard E. Gammans
Richard E. Gammans
Background and Purpose —Citicoline (cytidine-5′-diphosphocholine; CDP-choline) may reduce central nervous system ischemic injury by stabilizing cell membranes and reducing free radical generation. A previous dose-comparison trial in patients with acute stroke found that 500 mg of citicoline appeared to improve neurological outcome with minimal side effects. Methods —The current trial was a 33-center, randomized, double-blind, efficacy trial in 394 patients comparing placebo (n=127) with citicoline (n=267) (500 mg po daily) for 6 weeks, with a 6-week posttreatment follow-up period. Patients with acute (24 hours) ischemic strokes clinically assessed to be in the middle cerebral artery territory with National Institutes of Health Stroke Scale (NIHSS) ≥5 were enrolled. Results —Mean time to treatment was 12 hours, and mean age was 71 for placebo and 70 for citicoline. Although mean baseline NIHSS were similar for both groups, there was a higher percentage of placebo patients with NIHSS <8 (34% vs 22%; P <0.01). The incidence and type of side effects were similar between the groups. The planned primary analysis (logistic regression: 5 categories Barthel) failed the proportional odds assumption and was rendered unreliable. There were no between-group differences seen on the planned secondary assessment analyses at 90 days, including the Barthel Index ≥95 at 12 weeks (last observation carried forward: placebo 40%; citicoline 40%) or mortality rate (placebo 18%; citicoline 17%). However, post hoc analyses in a subgroup of patients with baseline NIHSS ≥8 found that citicoline-treated patients were more likely to have a full recovery (Barthel ≥95): placebo 21%; citicoline 33%; P =0.05; whereas no difference was seen in patients with baseline NIHSS0.1. Conclusions —The results of this study indicate that citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke who were enrolled in this trial. Post hoc analyses indicate that there may be a subgroup of patients with moderate to severe strokes who would benefit.

1 April 2001 in Stroke
Verified
Journal Article
Closed access
PDF file
WCWayne M. Clark
Wayne M. Clark
LRLisa G. Rinker
Lisa G. Rinker
NLNikola S. Lessov
Nikola S. Lessov
SLStuart L. Lowery
Stuart L. Lowery
MCMarilyn J. Cipolla
Marilyn J. Cipolla
Background and Purpose —Ginkgo biloba extract (EGb) and α-lipoic acid (LA) are commercially available “antioxidant supplements” with a variety of actions that may be beneficial during acute stroke. These actions include inhibiting platelet and leukocyte activation and adhesion, reducing free radical generation, and increasing cerebral blood flow. Both EGb and LA have been shown to be neuroprotective in cell culture and global central nervous system ischemia models. In this study we investigated the neuroprotective efficacy of EGb and LA in a clinically relevant, transient focal central nervous system ischemic model. Methods —In the EGb study, 60 adult C57blk mice were randomized to treatment with EGb given orally (via gavage) for 7 days: low dose, 50 EGb mg/kg daily; high dose, 100 mg/kg daily; matched placebo. On day 7, reversible middle cerebral artery occlusion was produced by advancing a silicone-coated 8-0 filament into the internal carotid artery for 45 minutes followed by reperfusion. At 24 hours, the animals were evaluated on a 28-point clinical scale, and infarct volume was determined with the use of triphenyltetrazolium chloride. In the LA study, 24 C57blk mice were treated with 100 mg/kg SC of LA or placebo 1.5 hours before transient MCAO, as in the EGb study. Results —In the EGb study, values for infarct volume at 24 hours were as follows (mean±SD): low dose (n=18), 13±5 mm 3 ; high dose (n=22), 22±12 mm 3 ; placebo (n=20), 20±10 mm 3 ( P =0.03 overall; P =0.02, low dose versus placebo). Infarct percentage of hemisphere values were as follows: low dose, 14±5%; high dose, 21±11%; placebo, 20±9% ( P =0.03 overall; P =0.02, low dose versus placebo). Ten percent of the high-dose group showed significant intracerebral hemorrhage (ICH) within the infarct, while no ICH was seen in the other groups. Neurological function scores were as follows: low dose, 11.8±1.5; high dose, 11.4±1.7; placebo, 11.3±1.8 ( P =NS). In the LA study, infarct volume was as follows: 100 mg/kg LA (n=12), 16.8±8.3 mm 3 ; placebo (n=12), 27.2±14.6 mm 3 ( P <0.05). LA also produced a significant improvement in neurological function at 24 hours: LA, 9.5±1.2; placebo, 11.2±1.8 ( P =0.02). There was no evidence of ICH in any of the animals. Conclusions —Both oral EGb and LA therapies produced significant reductions in stroke infarct volume. However, for EGb this beneficial effect appears to be dose related, with higher doses potentially increasing the risk of ICH.

26 August 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
RLRonald M. Lazar
Ronald M. Lazar
VWVirginia G. Wadley
Virginia G. Wadley
TMTerina Myers
Terina Myers
MJMichael R. Jones
Michael R. Jones
DHDonald V. Heck
Donald V. Heck
GHGeorge Howard
George Howard
Background and Purpose: Studies of carotid artery disease have suggested that high-grade stenosis can affect cognition, even without stroke. The presence and degree of cognitive impairment in such patients have not been reported and compared with a demographically matched population-based cohort. Methods: We studied cognition in 1000 consecutive CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) patients, a treatment trial for asymptomatic carotid disease. Cognitive assessment was after randomization but before assigned treatment. The cognitive battery was developed in the general population REGARDS Study (Reasons for Geographic and Racial Differences in Stroke), involving Word List Learning Sum, Word List Recall, and Word List fluency for animal names and the letter F. The carotid stenosis patients were >45 years old with ≥70% asymptomatic carotid stenosis and no history of prevalent stroke. The distribution of cognitive performance for the patients was standardized, accounting for age, race, and education using performance from REGARDS, and after further adjustment for hypertension, diabetes, dyslipidemia, and smoking. Using the Wald Test, we tabulated the proportion of Z scores less than the anticipated deviate for the population-based cohort for representative percentiles. Results: There were 786 baseline assessments. Mean age was 70 years, 58% men, and 52% right-sided stenosis. The overall Z score for patients was significantly below expected for higher percentiles ( P <0.0001 for 50th, 75th, and 95th percentiles) and marginally below expected for the 25th percentile ( P =0.015). Lower performance was attributed largely to Word List Recall ( P <0.0001 for all percentiles) and for Word List Learning (50th, 75th, and 95th percentiles below expected, P ≤0.01). The scores for left versus right carotid disease were similar. Conclusions: Baseline cognition of patients with severe carotid stenosis showed below normal cognition compared to the population-based cohort, controlling for demographic and cardiovascular risk factors. This cohort represents the largest group to date to demonstrate that poorer cognition, especially memory, in this disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02089217.